S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:CLSD

Clearside Biomedical (CLSD) Stock Forecast, Price & News

$1.38
-0.07 (-4.83%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.31
$1.49
50-Day Range
$1.36
$2.76
52-Week Range
$1.30
$7.73
Volume
266,208 shs
Average Volume
287,305 shs
Market Capitalization
$83.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.15
30 days | 90 days | 365 days | Advanced Chart
Receive CLSD News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

Clearside Biomedical logo

About Clearside Biomedical

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Headlines

Clearside Biomedical (NASDAQ:CLSD) Downgraded by TheStreet
Clearside Biomedical Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLSD
Employees
34
Year Founded
N/A

Sales & Book Value

Annual Sales
$29.58 million
Cash Flow
$0.01 per share
Book Value
$0.53 per share

Profitability

Net Income
$380 thousand
Pretax Margin
0.28%

Debt

Price-To-Earnings

Miscellaneous

Free Float
53,353,000
Market Cap
$83.01 million
Optionable
Optionable

Company Calendar

Last Earnings
5/11/2022
Today
5/22/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.97 out of 5 stars

Medical Sector

637th out of 1,416 stocks

Pharmaceutical Preparations Industry

293rd out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions

Is Clearside Biomedical a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Clearside Biomedical stock.
View analyst ratings for Clearside Biomedical
or view top-rated stocks.

When is Clearside Biomedical's next earnings date?

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Clearside Biomedical
.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) released its quarterly earnings data on Wednesday, May, 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.10. Clearside Biomedical had a trailing twelve-month return on equity of 0.31% and a net margin of 0.28%. During the same quarter in the previous year, the business posted ($0.13) EPS.
View Clearside Biomedical's earnings history
.

What price target have analysts set for CLSD?

4 analysts have issued 12 month price targets for Clearside Biomedical's stock. Their forecasts range from $9.00 to $15.00. On average, they anticipate Clearside Biomedical's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 697.1% from the stock's current price.
View analysts' price targets for Clearside Biomedical
or view top-rated stocks among Wall Street analysts.

Who are Clearside Biomedical's key executives?
Clearside Biomedical's management team includes the following people:
  • Dr. George M. Lasezkay Pharm.D., Pharma.D., J.D., Pres, CEO & Director (Age 70, Pay $681.67k)
  • Mr. Charles A. Deignan, Chief Financial Officer (Age 58, Pay $430.33k) (LinkedIn Profile)
  • Dr. Thomas A. Ciulla M.B.A., M.D., Chief Medical Officer & Chief Devel. Officer
  • Ms. Jenny R. Kobin, Head of Investor Relations (Age 55)
  • Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 53)
  • Mr. Rick McElheny, VP of Corp. Devel.
What other stocks do shareholders of Clearside Biomedical own?
When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Carmignac Gestion (4.13%), ACT Capital Management LLC (4.09%), Vanguard Group Inc. (3.60%), Assenagon Asset Management S.A. (1.52%), Renaissance Technologies LLC (1.44%) and State Street Corp (0.32%). Company insiders that own Clearside Biomedical stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, George M Lasezkay, Richard T Burke, Thomas Ciulla and William D Humphries.
View institutional ownership trends for Clearside Biomedical
.

Which major investors are selling Clearside Biomedical stock?

CLSD stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Carmignac Gestion, Group One Trading L.P., Goldman Sachs Group Inc., ACT Capital Management LLC, Principal Financial Group Inc., HAP Trading LLC, and Vanguard Group Inc.. Company insiders that have sold Clearside Biomedical company stock in the last year include Bradford T Whitmore, Charles A Deignan, George M Lasezkay, Richard T Burke, and Thomas Ciulla.
View insider buying and selling activity for Clearside Biomedical
or view top insider-selling stocks.

Which major investors are buying Clearside Biomedical stock?

CLSD stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Connor Clark & Lunn Investment Management Ltd., GSA Capital Partners LLP, Jane Street Group LLC, Synovus Financial Corp, XTX Topco Ltd, Simplex Trading LLC, and Bailard Inc.. Company insiders that have bought Clearside Biomedical stock in the last two years include Bradford T Whitmore, and William D Humphries.
View insider buying and selling activity for Clearside Biomedical
or or view top insider-buying stocks.

How do I buy shares of Clearside Biomedical?

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $1.38.

How much money does Clearside Biomedical make?

Clearside Biomedical has a market capitalization of $83.01 million and generates $29.58 million in revenue each year. The company earns $380 thousand in net income (profit) each year or ($0.01) on an earnings per share basis.

How many employees does Clearside Biomedical have?

Clearside Biomedical employs 34 workers across the globe.

What is Clearside Biomedical's official website?

The official website for Clearside Biomedical is www.clearsidebio.com.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at (678) 270-3631, via email at [email protected], or via fax at 678-270-4033.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.